Revolution Medicines (FRA:42Z) ROCE % : -30.24% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Revolution Medicines's annualized ROCE % for the quarter that ended in Mar. 2024 was -30.24%.

Revolution Medicines ROCE % Historical Data

The historical data trend for Revolution Medicines's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines ROCE % Chart

Revolution Medicines Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-33.05

-30.36

-32.23

-35.97

-32.68

Revolution Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-33.84	-42.95	-52.46	-37.34	-30.24

Revolution Medicines ROCE % Calculation

Revolution Medicines's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-403.102	/	( ( (766.462 - 58.513)	+	(1890.583 - 131.911) )	/ 2 )
	=	-403.102	/	( (707.949	+	1758.672)	/ 2 )
	=	-403.102	/	1233.3105
	=	-32.68 %

Revolution Medicines's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-518.36	/	( ( (1890.583 - 131.911)	+	(1755.693 - 86.225) )	/ 2 )
	=	-518.36	/	( ( 1758.672	+	1669.468 )	/ 2 )
	=	-518.36	/	1714.07
	=	-30.24 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Revolution Medicines (FRA:42Z) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Revolution Medicines ROCE % Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revolution Medicines (FRA:42Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RVMD:USA

Address

700 Saginaw Drive, Redwood City, CA, USA, 94063

Website

https://www.revmed.com

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines (FRA:42Z) Headlines

No Headlines